Neumora Therapeutics (NMRA) Set to Announce Earnings on Thursday

Neumora Therapeutics (NASDAQ:NMRA) will likely be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Neumora Therapeutics to post earnings of ($0.19) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.01. On average, analysts expect Neumora Therapeutics to post ($0.83) EPS for the current fiscal year and ($0.69) EPS for the next fiscal year.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $0.50 on Tuesday. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 4.50. The stock has a market cap of $93.14 million, a PE ratio of -0.40 and a beta of 2.95. The stock has a 50-day moving average of $0.77 and a 200-day moving average of $1.77. Neumora Therapeutics has a one year low of $0.32 and a one year high of $3.65.

Analysts Set New Price Targets

NMRA has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Royal Bank Of Canada cut their target price on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Weiss Ratings raised shares of Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 25th. Finally, Wall Street Zen cut shares of Neumora Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $6.57.

Insider Activity

In other news, insider Daljit Singh Aurora sold 21,055 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $1.60, for a total transaction of $33,688.00. Following the sale, the insider owned 48,750 shares of the company’s stock, valued at $78,000. This trade represents a 30.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 453,833 shares of company stock valued at $701,219 in the last ninety days. 26.94% of the stock is owned by corporate insiders.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders.

Neumora’s pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure.